A compound represented by Formula I: or a pharmaceutically acceptable salt or solvate thereof, wherein: A and B together represents (a) C1-4 alkylene optionally substituted with 1-3 halo groups, and 1-2 Ra groups in Ra represents C1-3alkyl, C1-3alkyl, arC6-10C1-6alkylene or phenyl optionally substituted with 1-3 halo groups, or (b) C2-5alkanediyl so that a 3-6 membered ring is formed with the carbon atom to which they are attached, optionally containing said double bond ring or 1-2 heteroatoms selected from O, S and N, said 3-6 membered ring being optionally substituted with C1-4 alkylene, oxo, ethylenedioxy or propylenedioxy, and being optionally substituted with 1-4 groups selected from halo, C1-4 alkyl, C1-4 haloalkyl, C1-3 acyl, C1-3 acyloxy, C1-3 alkoxy, C1-6OC (O) alkyl, alkenyl C2-4, C2-4 alkynyl, C1-3 alkoxy C1-3 alkyl, C1-3 alkoxy C1-3 alkoxy, phenyl, CN, OH, D, NH2, NHRa and N (Ra) 2 in 1 Ra is as previously defined； each R1 represents H or is independently selected from the group consisting of: OH, halo, C1-10 alkyl, C1-6 alkoxy and C1-10 aryl, said C1-10 alkyl, C6-10 aryl and the C1-6 alkoxy alkyl part being optionally substituted with 1-3 halo, OH, C1-3alkyl, phenyl or naphthyl groups, said phenyl and naphthyl being optionally substituted with 1-3 substituents independently selected from halo, OCH3, OCF3, CH3, CF3 and phenyl, wherein said phenyl it is optionally substituted with 1-3 halo groups, or two R1 groups taken together represent a C5-6 alkyl or aryl ring, which may be optionally substituted with 1-2 OH or Ra groups, in which Ra is as defined above； R2 and R3 are taken together or separately； when taken together, R2 and R3 represent (a) a C 3-8 alkanediyl that forms a non-aromatic 5-10 membered fused ring optionally interrupted with 1-2 double bonds, and optionally interrupted by 1-2 heteroatoms selected from O , S and N； or (b) a 6-10 membered monocyclic or bicyclic aromatic fused group, said monocyclic or bicyclic alkanediyl and aromatic group
